Seymour, J., Aw, A., Ribrag, V., Cartron, G., Kater, A., Eom, K., Skarbnik, A., Tedeschi, A., Wach, M., Hou, J., Illes, A., Suterwala, B., Munley, J., John, E., Fujimori, T., Brown, J. (2025). A post hoc safety analysis of fixed-duration acalabrutinib-venetoclax combinations vs chemoimmunotherapy: Results from the phase 3 AMPLIFY trial. Blood. https://doi.org/10.1182/blood-2025-2118